From Wikipedia, the free encyclopedia
Jump to: navigation, search
Systematic (IUPAC) name
Glucurono-2-amino-2-deoxyglucoglucan sulfate
Clinical data
AHFS/ International Drug Names
Routes of
Oral, Subcutaneous, Intravenous, Intramuscular
CAS Number 57821-29-1 YesY
ATC code B01AB11
DrugBank DB06271 YesY
KEGG D08547 YesY

Sulodexide is a highly purified mixture of glycosaminoglycans composed of low molecular weight heparin (80%) and dermatan sulfate (20%).


The low molecular weight of both sulodexide fractions allows for extensive oral absorption compared to unfractionated heparin. The pharmacological effects of sulodexide differ substantially from other glycosaminoglycans and are mainly characterized by a prolonged half-life and reduced effect on global coagulation and bleeding parameters.[1] Due to the presence of both glycosaminoglycan fractions, sulodexide potentiates the antiprotease activities of both antithrombin III and heparin cofactor II simultaneously.[2]


Clinically, sulodexide is used for the prophylaxis and treatment of thromboembolic diseases however recent research has also demonstrated the beneficial effects of sulodexide in animal models of reperfusion injury[3] and the treatment of diabetic nephropathy.[4][5][6] In combination with Melatonin, Sulodexide have been shown to be a viable treatment option for patients suffering from central or sensorineural tinnitus.[7][8]


  1. ^ Lauver DA, Lucchesi BR (2006). "Sulodexide: a renewed interest in this glycosaminoglycan". Cardio drug rev 24 (3-4): 214–26. doi:10.1111/j.1527-3466.2006.00214.x. PMID 17214598. 
  2. ^ Harenberg J (1998). "Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide". Med Res Rev 18 (1): 1–20. doi:10.1002/(SICI)1098-1128(199801)18:1<1::AID-MED1>3.0.CO;2-4. PMID 9436179. 
  3. ^ Lauver DA, Booth EA, White AJ, Poradosu E, Lucchesi BR (2005). "Sulodexide attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis". J Pharmacol Exp Ther 312 (2): 794–800. doi:10.1124/jpet.104.075283. PMID 15365091. 
  4. ^ Achour A, Kacem M, Dibej K, Skhiri H, Bouraoui S, El May M. (2005). "One year course of oral sulodexide in the management of diabetic nephropathy". J Nephrol 18 (5): 568–574. PMID 16299683. 
  5. ^ Gambaro G, Venturini AP, Noonan DM, et al. (1994). "Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy". Kidney Int 46 (3): 797–806. doi:10.1038/ki.1994.335. PMID 7527876. 
  6. ^ Škrhaa J, , J Perušičováb J; et al. (1997). "Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy". Diabetes Res Clin Practice 38 (1): 25–31. doi:10.1016/S0168-8227(97)00076-4. PMID 9347243. 
  7. ^ Neri G, Baffa C, De Stefano A, et al. (2009). "Management of tinnitus: oral treatment with melatonin and sulodexide". J. Biol. Regul. Homeost. Agents 23 (2): 103–10. PMID 19589291. 
  8. ^ Neri G. De Stefano A. Baffa C. Kulamarva G. Di Giovanni P. Petrucci G. Poliandri A. Dispenza F. Citraro L. Croce A. ,"Treatment of central and sensorineural tinnitus with orally administered Melatonin and Sulodexide: personal experience from a randomized controlled study." Acta Otorhinolaryngologica Italica. 29(2):86-91, 2009 Apr.

External links[edit]